Skip to main content

Advertisement

Log in

Neuroimaging classification of progression patterns in glioblastoma: a systematic review

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Background

Our primary objective was to report the current neuroimaging classification systems of spatial patterns of progression in glioblastoma. In addition, we aimed to report the terminology used to describe ‘progression’ and to assess the compliance with the Response Assessment in Neuro-Oncology (RANO) Criteria.

Methods

We conducted a systematic review to identify all neuroimaging studies of glioblastoma that have employed a categorical classification system of spatial progression patterns. Our review was registered with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) registry.

Results

From the included 157 results, we identified 129 studies that used labels of spatial progression patterns that were not based on radiation volumes (Group 1) and 50 studies that used labels that were based on radiation volumes (Group 2). In Group 1, we found 113 individual labels and the most frequent were: local/localised (58%), distant/distal (51%), diffuse (20%), multifocal (15%) and subependymal/subventricular zone (15%). We identified 13 different labels used to refer to ‘progression’, of which the most frequent were ‘recurrence’ (99%) and ‘progression’ (92%). We identified that 37% (n = 33/90) of the studies published following the release of the RANO classification were adherent compliant with the RANO criteria.

Conclusions

Our review reports significant heterogeneity in the published systems used to classify glioblastoma spatial progression patterns. Standardization of terminology and classification systems used in studying progression would increase the efficiency of our research in our attempts to more successfully treat glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18:v1–v75

    Article  PubMed  Google Scholar 

  2. Price SJ, Gillard JH (2011) Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 84:S159–S167

    Article  PubMed  PubMed Central  Google Scholar 

  3. Friedmann-Morvinski D (2014) Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 19:327–336

    Article  PubMed  Google Scholar 

  4. Zhang W, Le TD, Liu L et al (2017) Mining heterogeneous causal effects for personalized cancer treatment. Bioinformatics 33:2372–2378

    Article  PubMed  Google Scholar 

  5. Filippini G, Falcone C, Boiardi A et al (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911

    Article  PubMed  CAS  Google Scholar 

  7. Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27:1275–1279

    Article  PubMed  CAS  Google Scholar 

  8. De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115:37–43

    Article  PubMed  Google Scholar 

  9. Kim J, Lee I-H, Cho HJ et al (2015) Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28:318–328

    Article  PubMed  CAS  Google Scholar 

  10. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972

    Article  PubMed  Google Scholar 

  11. Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307–320

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bähr O, Harter PN, Weise LM et al (2014) Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 83:227–234

    Article  PubMed  CAS  Google Scholar 

  13. Choi SH, Kim JW, Chang JS et al (2017) Impact of including peritumoral edema in radiotherapy target volume on patterns of failure in glioblastoma following temozolomide-based chemoradiotherapy. Sci Rep 7:42148

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Lundemann M, Costa JC, Law I et al (2017) Patterns of failure for patients with glioblastoma following O-(2-[(18)F]fluoroethyl)-l-tyrosine PET- and MRI-guided radiotherapy. Radiother Oncol 122:380–386

    Article  PubMed  Google Scholar 

  15. Fujimura M, Kumabe T, Jokura H et al (2004) Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma. J Neurooncol 66:209–216

    Article  PubMed  Google Scholar 

  16. Blumenthal DT, Artzi M, Liberman G et al (2017) Classification of high-grade glioma into tumor and nontumor components using support vector machine. Am J Neuroradiol 38:908–914

    Article  PubMed  CAS  Google Scholar 

  17. Cachia D, Elshafeey NA, Kamiya-Matsuoka C et al (2017) Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 135:75–81

    Article  PubMed  CAS  Google Scholar 

  18. Rapp M, Baernreuther J, Turowski B et al (2017) Recurrence pattern analysis of primary glioblastoma. World Neurosurg 103:733–740

    Article  PubMed  Google Scholar 

  19. Straube C, Elpula G, Gempt J et al (2017) Re-irradiation after gross total resection of recurrent glioblastoma: spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol 193:897–909

    Article  PubMed  Google Scholar 

  20. Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64

    Article  PubMed  CAS  Google Scholar 

  21. Sneed PK, McDermott MW, Gutin PH (1997) Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157–166

    Article  PubMed  CAS  Google Scholar 

  22. Khalifa J, Tensaouti F, Lusque A et al (2017) Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 12:67

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Kondo N, Barth RF, Miyatake S-I et al (2017) Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1(R132H) mutation-negative glioblastoma. J Neurooncol 133:107–118

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Agarwal A, Kumar S, Narang J et al (2013) Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol 112:413–420

    Article  PubMed  Google Scholar 

  25. Agbi CB, Bernstein M, Laperriere N et al (1992) Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 23:321–326

    Article  PubMed  CAS  Google Scholar 

  26. Aiken AH, Chang SM, Larson D et al (2008) Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 72:1340–1346

    Article  PubMed  Google Scholar 

  27. Albert FK, Forsting M, Sartor K et al (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–60

    PubMed  CAS  Google Scholar 

  28. Alexander E, Loeffler JS (1998) Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14:43–52

    Article  PubMed  Google Scholar 

  29. Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 16:823–828

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Antoni D, Jastaniah Z, Haoming QC et al (2016) Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Cancer Radiother 20:282–291

    Article  PubMed  CAS  Google Scholar 

  31. Aydin H, Sillenberg I, von Lieven H (2001) Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 177:424–431

    Article  PubMed  CAS  Google Scholar 

  32. Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564

    Article  PubMed  Google Scholar 

  33. Bashir R, Hochberg F, Oot R (1988) Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27–30

    Article  PubMed  CAS  Google Scholar 

  34. Becker G, Hofmann E, Woydt M et al (1999) Postoperative neuroimaging of high-grade gliomas: comparison of transcranial sonography, magnetic resonance imaging, and computed tomography. Neurosurgery 44:469–477

    Article  PubMed  CAS  Google Scholar 

  35. Bernstein M, Laperriere N, Glen J et al (1994) Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30:1213–1217

    Article  PubMed  CAS  Google Scholar 

  36. Biswas A, Kumar N, Kumar P et al (2011) Primary gliosarcoma-clinical experience from a regional cancer centre in north India. Br J Neurosurg 25:723–729

    Article  PubMed  Google Scholar 

  37. Bloch O, Safaee M, Sun MZ et al (2013) Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 115:1795–1801

    Article  PubMed  PubMed Central  Google Scholar 

  38. Bokstein F, Kovner F, Blumenthal DT et al (2008) A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. Int J Radiat Oncol Biol Phys 72:900–904

    Article  PubMed  Google Scholar 

  39. Buglione M, Pedretti S, Poliani PL et al (2016) Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: could a margin reduction be proposed? J Neurooncol 128:303–312

    Article  PubMed  CAS  Google Scholar 

  40. Burger MC, Mildenberger IC, Wagner M et al (2017) Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern. Int J Mol Sci 18:E726

    Article  PubMed  CAS  Google Scholar 

  41. Burger PC, Dubois PJ, Schold SC et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169

    Article  PubMed  CAS  Google Scholar 

  42. Chamberlain MC, Barba D, Kormanik P, Shea WM (1994) Stereotactic radiosurgery for recurrent gliomas. Cancer 74:1342–1347

    Article  PubMed  CAS  Google Scholar 

  43. Chamberlain MC (2011) Radiographic patterns of relapse in glioblastoma. J Neurooncol 101:319–323

    Article  PubMed  Google Scholar 

  44. Champ CE, Siglin J, Mishra MV et al (2012) Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas. Radiat Oncol 7:220

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chan DTM, Hsieh SYP, Kam MKM et al (2016) Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. Surg Neurol Int 7:92

    Article  PubMed  PubMed Central  Google Scholar 

  46. Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642

    Article  PubMed  Google Scholar 

  47. Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150

    Article  PubMed  Google Scholar 

  48. Chen L, Chaichana KL, Kleinberg L et al (2015) Glioblastoma recurrence patterns near neural stem cell regions. Radiother Oncol 116:294–300

    Article  PubMed  PubMed Central  Google Scholar 

  49. Cho KH, Kim J-Y, Lee SH et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 78:390–397

    Article  PubMed  Google Scholar 

  50. Choucair AK, Levin VA, Gutin PH et al (1986) Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654–658

    Article  PubMed  CAS  Google Scholar 

  51. Colen RR, Zinn PO, Hazany S et al (2011) Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study. World J Radiol 3:266–272

    Article  PubMed  PubMed Central  Google Scholar 

  52. Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302–1312

    Article  PubMed  CAS  Google Scholar 

  53. Dobelbower MC, Burnett Iii OL, Nordal RA et al (2011) Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 55:77–81

    Article  PubMed  Google Scholar 

  54. Dörner L, Mustafa A, Rohr A et al (2013) Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci 20:429–434

    Article  PubMed  CAS  Google Scholar 

  55. Douglas JG, Stelzer KJ, Mankoff DA et al (2006) [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64:886–891

    Article  PubMed  CAS  Google Scholar 

  56. Eisele G, Wick A, Eisele A-C et al (2014) Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 117:141–145

    Article  PubMed  CAS  Google Scholar 

  57. Ekinci G, Akpinar IN, Baltacioğlu F et al (2003) Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence. Eur J Radiol 45:99–107

    Article  PubMed  Google Scholar 

  58. Elson A, Paulson E, Bovi J et al (2015) Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. J Neurooncol 123:179–188

    Article  PubMed  CAS  Google Scholar 

  59. Elzinga G, Wong ET (2014) Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. Case Rep Neurol 6:109–115

    Article  PubMed  PubMed Central  Google Scholar 

  60. Farina P, Tabouret E, Lehmann P et al (2017) Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. J Neurooncol 132:433–437

    Article  PubMed  CAS  Google Scholar 

  61. Forsting M, Albert FK, Kunze S et al (1993) Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14:77–87

    PubMed  CAS  Google Scholar 

  62. Gállego Pérez-Larraya J, Lahutte M, Petrirena G et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14:667–673

    Article  PubMed  CAS  Google Scholar 

  63. Garden AS, Maor MH, Yung WK et al (1991) Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20:99–110

    Article  PubMed  CAS  Google Scholar 

  64. Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57

    Article  PubMed  CAS  Google Scholar 

  65. Gebhardt BJ, Dobelbower MC, Ennis WH et al (2014) Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 9:130

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Giese A, Kucinski T, Knopp U et al (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360

    Article  PubMed  Google Scholar 

  67. Gobitti C, Borsatti E, Arcicasa M et al (2011) Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori 97:614–619

    Article  PubMed  Google Scholar 

  68. Gunjur A, Bressel M, Ryan G (2012) The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. J Med Imaging Radiat Oncol 56:567–573

    Article  PubMed  Google Scholar 

  69. Halligan JB, Stelzer KJ, Rostomily RC et al (1996) Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 35:541–547

    Article  PubMed  CAS  Google Scholar 

  70. Heros DO, Renkens K, Kasdon DL, Adelman LS (1988) Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. Neurosurgery 22:474–478

    Article  PubMed  CAS  Google Scholar 

  71. Hess CF, Schaaf JC, Kortmann RD et al (1994) Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146–149

    Article  PubMed  CAS  Google Scholar 

  72. Houston SC, Crocker IR, Brat DJ, Olson JJ (2000) Extraneural metastatic glioblastoma after interstitial brachytherapy. Int J Radiat Oncol Biol Phys 48:831–836

    Article  PubMed  CAS  Google Scholar 

  73. Iuchi T, Hatano K, Kodama T et al (2014) Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 88:793–800

    Article  PubMed  CAS  Google Scholar 

  74. Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317–1324

    Article  PubMed  Google Scholar 

  75. Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Jastaniyah N, Murtha A, Pervez N et al (2013) Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol 8:38

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Jia A, Pannullo SC, Minkowitz S et al (2016) Innovative hypofractionated stereotactic regimen achieves excellent local control with no radiation necrosis: promising results in the management of patients with small recurrent inoperable GBM. Cureus 8:e536

    PubMed  PubMed Central  Google Scholar 

  78. Kim BR, Choi SH, Yun TJ et al (2016) MR Imaging analysis of non-measurable enhancing lesions newly appearing after concomitant chemoradiotherapy in glioblastoma patients for prognosis prediction. PLoS ONE 11:e0166096

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Kim BS, Kim SK, Choi SH et al (2015) Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol 124:101–110

    Article  PubMed  CAS  Google Scholar 

  80. Kim C-S, Jung S, Jung T-Y et al (2011) Characterization of invading glioma cells using molecular analysis of leading-edge tissue. J Korean Neurosurg Soc 50:157–165

    Article  PubMed  PubMed Central  Google Scholar 

  81. Kimura M, Lee Y, Miller R, Castillo M (2013) Glioblastoma multiforme: relationship to subventricular zone and recurrence. Neuroradiol J 26:542–547

    Article  PubMed  PubMed Central  Google Scholar 

  82. Konishi Y, Muragaki Y, Iseki H et al (2012) Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases. Neurol Med Chir 52:577–586

    Article  Google Scholar 

  83. Kyritsis AP, Levin VA, Yung WK, Leeds NE (1993) Imaging patterns of multifocal gliomas. Eur J Radiol 16:163–170

    Article  PubMed  CAS  Google Scholar 

  84. Larson DA, Prados M, Lamborn KR et al (2002) Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54:1397–1404

    Article  PubMed  Google Scholar 

  85. Lee IH, Piert M, Gomez-Hassan D et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:479–485

    Article  PubMed  CAS  Google Scholar 

  86. Lee SW, Fraass BA, Marsh LH et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88

    Article  PubMed  CAS  Google Scholar 

  87. Liang BC, Thornton AF, Sandler HM, Greenberg HS (1991) Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559–563

    Article  PubMed  CAS  Google Scholar 

  88. Lim DA, Cha S, Mayo MC et al (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424–429

    Article  PubMed  PubMed Central  Google Scholar 

  89. Loeffler JS, Alexander E, Hochberg FH et al (1990) Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 19:1455–1462

    Article  PubMed  CAS  Google Scholar 

  90. Majós C, Cos M, Castañer S et al (2016) Preradiotherapy MR imaging: a prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma. Am J Neuroradiol 37:2224–2230

    Article  PubMed  Google Scholar 

  91. Mamo A, Baig A, Azam M et al (2016) Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol 23:e468–e471

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Masciopinto JE, Levin AB, Mehta MP, Rhode BS (1995) Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 82:530–535

    Article  PubMed  CAS  Google Scholar 

  93. Massey V, Wallner KE (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398

    Article  PubMed  CAS  Google Scholar 

  94. Matsuda M, Ishikawa E, Yamamoto T et al (2017) Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. J Clin Neurosci 40:115–119

    Article  PubMed  CAS  Google Scholar 

  95. Matsuda M, Yamamoto T, Kumada H et al (2009) Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy. Appl Radiat Isot 67:S19–S21

    Article  PubMed  CAS  Google Scholar 

  96. McDonald MW, Shu H-KG, Curran WJ, Crocker IR (2011) Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 79:130–136

    Article  PubMed  CAS  Google Scholar 

  97. Mehta MP, Masciopinto J, Rozental J et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541–549

    Article  PubMed  CAS  Google Scholar 

  98. Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N et al (2015) Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 123:141–150

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147–1155

    Article  PubMed  CAS  Google Scholar 

  100. Minniti G, Amelio D, Amichetti M et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377–381

    Article  PubMed  CAS  Google Scholar 

  101. Monjazeb AM, Ayala D, Jensen C et al (2012) A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 82:743–748

    Article  PubMed  Google Scholar 

  102. Murakami R, Hirai T, Nakamura H et al (2012) Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol 30:193–197

    Article  PubMed  CAS  Google Scholar 

  103. Nakagawa K, Aoki Y, Fujimaki T et al (1998) High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:1141–1149

    Article  PubMed  CAS  Google Scholar 

  104. Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180

    Article  PubMed  Google Scholar 

  105. Narayana A, Kunnakkat SD, Medabalmi P et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 82:77–82

    Article  PubMed  Google Scholar 

  106. Narayana A, Golfinos JG, Fischer I et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383–389

    Article  PubMed  CAS  Google Scholar 

  107. Narayana A, Gruber D, Kunnakkat S et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345

    Article  PubMed  CAS  Google Scholar 

  108. Narayana A, Perretta D, Kunnakkat S et al (2011) Invasion is not an independent prognostic factor in high-grade glioma. J Cancer Res Ther 7:331–335

    Article  PubMed  Google Scholar 

  109. Nestler U, Lutz K, Pichlmeier U et al (2015) Anatomic features of glioblastoma and their potential impact on survival. Acta Neurochir 157:179–186

    Article  PubMed  CAS  Google Scholar 

  110. Niyazi M, Jansen NL, Rottler M et al (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 9:299

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Niyazi M, Schnell O, Suchorska B et al (2012) FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 104:78–82

    Article  PubMed  Google Scholar 

  112. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    Article  PubMed  CAS  Google Scholar 

  113. Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82:1684–1692

    Article  PubMed  CAS  Google Scholar 

  114. Ogura K, Mizowaki T, Arakawa Y et al (2013) Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol 8:97

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Oh J, Sahgal A, Sanghera P et al (2011) Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 38:621–625

    Article  PubMed  Google Scholar 

  116. Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57

    Article  PubMed  CAS  Google Scholar 

  117. Pan H, Alksne J, Mundt AJ et al (2012) Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Med Oncol 29:2040–2045

    Article  PubMed  CAS  Google Scholar 

  118. Panet-Raymond V, Souhami L, Roberge D et al (2009) Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73:473–478

    Article  PubMed  CAS  Google Scholar 

  119. Park I, Tamai G, Lee MC et al (2007) Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 69:381–389

    Article  PubMed  PubMed Central  Google Scholar 

  120. Petrecca K, Guiot M-C, Panet-Raymond V, Souhami L (2013) Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 111:19–23

    Article  PubMed  Google Scholar 

  121. Piroth MD, Galldiks N, Pinkawa M et al (2016) Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 11:87

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437

    Article  PubMed  CAS  Google Scholar 

  123. Price SJ, Jena R, Burnet NG et al (2007) Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 17:1675–1684

    Article  PubMed  Google Scholar 

  124. Puchner MJA, Giese A, Lohmann F, Cristante L (2004) High-dose tamoxifen treatment increases the incidence of multifocal tumor recurrences in glioblastoma patients. Anticancer Res 24:4195–4203

    PubMed  CAS  Google Scholar 

  125. Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297–5305

    Article  PubMed  CAS  Google Scholar 

  126. Rostomily RC, Spence AM, Duong D et al (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388 (discussion 388)

    Article  PubMed  CAS  Google Scholar 

  127. Schaub C, Greschus S, Seifert M et al (2013) FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 85:191–195

    Article  PubMed  CAS  Google Scholar 

  128. Schupak K, Malkin M, Anderson L et al (1995) The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys 32:1167–1176

    Article  PubMed  CAS  Google Scholar 

  129. Shapiro LQ, Beal K, Goenka A et al (2013) Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 85:636–642

    Article  PubMed  CAS  Google Scholar 

  130. Sharma RR, Singh DP, Pathak A et al (2003) Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurol India 51:512–517

    PubMed  CAS  Google Scholar 

  131. Sherriff J, Tamangani J, Senthil L et al (2013) Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 86:20120414

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Shibahara I, Sonoda Y, Saito R et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15:1151–1159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  133. Shields LBE, Kadner R, Vitaz TW, Spalding AC (2013) Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Radiat Oncol 8:101

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Shimato S, Nishizawa T, Ohshima T et al (2016) Patterns of recurrence after resection of malignant gliomas With BCNU wafer implants: retrospective review in a single institution. World Neurosurg 90:340–347

    Article  PubMed  Google Scholar 

  135. Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824

    Article  PubMed  Google Scholar 

  136. Soffietti R, Trevisan E, Bertero L et al (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 116:533–541

    Article  PubMed  CAS  Google Scholar 

  137. Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93 - 05 protocol. Int J Radiat Oncol Biol Phys 60:853–860

    Article  PubMed  Google Scholar 

  138. Stall B, Zach L, Ning H et al (2010) Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol 5:5

    Article  PubMed  PubMed Central  Google Scholar 

  139. Stummer W, Beck T, Beyer W et al (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurooncol 87:103–109

    Article  PubMed  CAS  Google Scholar 

  140. Suzuki M, Nakamatsu K, Kanamori S et al (2003) Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 33:271–277

    Article  PubMed  Google Scholar 

  141. Takano S, Mashiko R, Osuka S et al (2010) Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol 27:89–94

    Article  PubMed  CAS  Google Scholar 

  142. Tang W, Wang X, Chen Y et al (2015) CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol 63:190–198

    Article  PubMed  CAS  Google Scholar 

  143. Tejada S, Aldave G, Marigil M et al (2014) Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol 116:169–175

    Article  PubMed  CAS  Google Scholar 

  144. Torok JA, Wegner RE, Mintz AH et al (2011) Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 10:253–258

    Article  PubMed  CAS  Google Scholar 

  145. Trifiletti DM, Hill C, Garda A et al (2017) Multilesion glioblastoma multiforme in the modern chemo-radiotherapy era: an analysis of pattern of failure and overall survival. J Radiat Oncol 6:57–63

    Article  CAS  Google Scholar 

  146. Tsien CI, Brown D, Normolle D et al (2012) Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 18:273–279

    Article  PubMed  CAS  Google Scholar 

  147. Tsuboi K, Yoshii Y, Nakagawa K, Maki Y (1986) Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. Neurosurgery 19:946–951

    Article  PubMed  CAS  Google Scholar 

  148. Tuettenberg J, Grobholz R, Seiz M et al (2009) Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135:1239–1244

    Article  PubMed  CAS  Google Scholar 

  149. Uehara K, Sasayama T, Miyawaki D et al (2012) Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. Radiat Oncol 7:104

    Article  PubMed  PubMed Central  Google Scholar 

  150. Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409

    Article  PubMed  CAS  Google Scholar 

  151. Weber DC, Casanova N, Zilli T et al (2009) Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 93:586–592

    Article  PubMed  Google Scholar 

  152. Welsh J, Sanan A, Gabayan AJ et al (2007) GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68:159–165

    Article  PubMed  Google Scholar 

  153. Wick W, Chinot OL, Bendszus M et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18:1434–1441

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  154. Wick W, Stupp R, Beule A-C et al (2008) A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 10:1019–1024

    Article  PubMed  PubMed Central  Google Scholar 

  155. Wick A, Dörner N, Schäfer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586–592. https://doi.org/10.1002/ana.22336

    Article  PubMed  Google Scholar 

  156. Wismeth C, Dudel C, Pascher C et al (2010) Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results. J Neurooncol 98:395–405

    Article  PubMed  CAS  Google Scholar 

  157. Yanagihara TK, Grinband J, Rowley J et al (2016) A simple automated method for detecting recurrence in high-grade glioma. Am J Neuroradiol 37:2019–2025

    Article  CAS  PubMed  Google Scholar 

  158. Yoo R-E, Choi SH, Kim TM et al (2015) Independent poor prognostic factors for true progression after radiation therapy and concomitant temozolomide in patients with glioblastoma: subependymal enhancement and low ADC value. Am J Neuroradiol 36:1846–1852

    Article  PubMed  Google Scholar 

  159. Young RJ, Gupta A, Shah AD et al (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918–1924

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  160. Zhou X, Liao X, Zhang B et al (2016) Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol 5:289–294

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  161. Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336

    Article  PubMed  CAS  Google Scholar 

  162. Zuniga RM, Torcuator R, Jain R et al (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 99:237–242

    Article  PubMed  CAS  Google Scholar 

  163. Sneed PK, Gutin PH, Larson DA et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727

    Article  PubMed  CAS  Google Scholar 

  164. Adeberg S, König L, Bostel T et al (2014) Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. Int J Radiat Oncol Biol Phys 90:886–893

    Article  PubMed  Google Scholar 

  165. Kim J-H, Jung T-Y, Hwang EC et al (2017) Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. Oncol Lett 14:3529–3535

    Article  PubMed  PubMed Central  Google Scholar 

  166. Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    Article  PubMed  CAS  Google Scholar 

  167. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  168. Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461

    Article  PubMed  Google Scholar 

  169. Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410

    Article  PubMed  CAS  Google Scholar 

  170. Shapiro WR (1999) Current therapy for brain tumors: back to the future. Arch Neurol 56:429–432

    Article  PubMed  CAS  Google Scholar 

  171. Price SJ, Jena R, Burnet NG et al (2006) Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. Am J Neuroradiol 27:1969–1974

    PubMed  CAS  Google Scholar 

  172. Price MS, Matys DT, Joannides DA et al (2017) OP04. Predicting sites of treatment failure and tumour recurrence in the invasive margin of glioblastomas (PRAM-GBM)—trial. Neuro Oncol 19:i24–i25

    Article  PubMed Central  Google Scholar 

  173. Macleod MR, Michie S, Roberts I et al (2014) Biomedical research: increasing value, reducing waste. Lancet 383:101–104

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rory J. Piper.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piper, R.J., Senthil, K.K., Yan, JL. et al. Neuroimaging classification of progression patterns in glioblastoma: a systematic review. J Neurooncol 139, 77–88 (2018). https://doi.org/10.1007/s11060-018-2843-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2843-3

Keywords

Navigation